Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-World, Retrospective, Multicenter Study to Assess the Effectiveness and Safety of Mayzent® (Siponimod) in Chinese Patients With Relapsing Forms of Multiple Sclerosis

NCT06395909 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT06395909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06395909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-World, Retrospective, Multicenter Study to Assess the Effectiveness and Safety of Mayzent® (Siponimod) in Chinese Patients With Relapsing Forms of Multiple Sclerosis
Lead sponsor
Novartis
Phase
Observational
Overall status
Completed
Start date
April 23, 2023
Completion date
August 31, 2023
Enrollment
113 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinically isolated syndrome, relapsing multiple sclerosis, relapsing remitting multiple sclerosis, secondary progressive multiple sclerosis